[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351677-105":59,"doc-detail-351677-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","novel-multiplex-immunofluorescence-based-tumor-inflammation-score-provides-apparent-predictive-biomarker-in-a-phase-iii-study-of-pembrolizumab-with-gemcitabine","Novel multiplex immunofluorescence-based tumor inflammation score provides apparent predictive biomarker in a phase I/II study of pembrolizumab with gemcitabine","","Retrospective analysis of tumor microenvironment cell-to-cell relationships shows stronger predictive capacity than PD-L1 expression, tumor mutational burden (TMB), or gene expression profiles in immunotherapy-naïve advanced NSCLC. In a small phase I/II feasibility study of gemcitabine plus pembrolizumab in 16 previously treated patients, the combination was safely administered without clear synergy versus historical controls. Baseline regulatory T cell proximity to CD3 T cells correlated with improved outcomes (p \u003C 0.05), and a tumor inflammation score combining this relationship with overall T-cell density associated with disease response (p \u003C 0.002), suggesting an ongoing anticancer immune response.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/novel-multiplex-immunofluorescence-based-tumor-inflammation-score-provides-apparent-predictive-biomarker-in-a-phase-iii-study-of-pembrolizumab-with-gemcitabine/351677/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/novel-multiplex-immunofluorescence-based-tumor-inflammation-score-provides-apparent-predictive-biomarker-in-a-phase-iii-study-of-pembrolizumab-with-gemcitabine/351677.png","ImageObject",300,407,{"name":92,"@type":93},"Cart","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What does the study suggest about predicting response in advanced NSCLC?","Question",{"text":112,"@type":113},"Cell-to-cell relationships in the tumor microenvironment provide significantly better predictive power than PD-L1 expression, TMB, or gene expression profiles.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What immune feature at baseline was associated with better treatment outcome?",{"text":117,"@type":113},"Higher frequencies of regulatory T cells near CD3 T cells at baseline correlated with improved outcome (p \u003C 0.05).",{"name":119,"@type":110,"acceptedAnswer":120},"How did the tumor inflammation score relate to disease response?",{"text":121,"@type":113},"Combining the Treg/T cell relationship metric with overall T-cell density produced a tumor inflammation score that correlated with disease response (p \u003C 0.002).","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351677,1790388348,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},18829141979164,"https://eur-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","ONCOIMMUNOLOGY  \n2026, VOL. 15, NO. 1, 2661444  \n[https://doi.org/10.1080/2162402X.2026.2661444](https://doi.org/10.1080/2162402X.2026.2661444)  \nRESEARCH ARTICLE     \nNovel multiplex immunofluorescence-based tumor inflammation score provides apparent predictive biomarker in a phase I/II study of pembrolizumab with gemcitabine in patients with previously-treated advanced non-small cell lung cancer (NSCLC)  \nRachel E. Sanborna, Shawn M. Jensena, Christopher Paustiana, Shu-Ching Changa, Eloy Vettoa, Quyen Vua, Venkatesh Rajamanickama, Brady Bernarda, Yoshinobu Koguchia, William L. Redmonda, band Bernard A. Foxa, b   \naRobert W. Franz Cancer Center, Earle A. Chiles Research Institute, Providence Cancer Institute, Providence Portland Medical Center, Portland, OR, USA; bDepartment of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, OR, USA  \nABSTRACT  \nRetrospective characterization of cell‒cell relationships in the tumor microenvironment provides significantly better predictive power than PD-L1 expression, tumor mutational burden (TMB), or gene expression profiles. In this small study assessing the safety and possible efficacy of gemcitabine and pembrolizumab in immunotherapy-naïve patients with NSCLC who have received prior treatment, we investigated both standard and novel immune parameters in 16 enrolled patients (NCT03083808) . The combination of gemcitabine and pembrolizumab could be administered safely but did not demonstrate synergism compared with historical controls. Novel findings of this study are that elevated frequencies of regulatory T cells near CD3 T cells at baseline were associated with improved outcome to treatment (p \u003C 0.05) . Integrating this Treg/T cell relationship metric together with overall T-cell density yielded a tumor inflammation score that correlated (p \u003C 0.002) with disease response. We postulate that this is indicative of an ongoing anticancer immune response. Additionally, while prior studies documented that IgG Ab responses to TAA can identify targets of a coordinated T and B cell response and evidence of immune surveillance, this study found that high autoantibody responses, while not statistically significant, trended toward a worse outcome (p = 0.06) . This suggests to us that tumors may have developed mechanisms to escape the immune response to these TAAs.  \nARTICLE HISTORY  \nReceived 9 June 2025 Revised 23 February 2026 Accepted 1 April 2026  \nKEYWORDS  \nTumor microenvironment; immune response; multiplex immunofluorescence (mIF); seromics; biomarkers; tumor-associated antigens (TAA); antibody response; Treg/T cell relationship  \nIntroduction  \nNon-small-cell lung cancer (NSCLC) is the most common cancer killer. 1,2 Checkpoint inhibitors have significantly improved survival for patients with advanced NSCLC,3-6 although the benefit is limited for the majority of patients,5,7-10 and improved therapeutic approaches are needed.  \nGemcitabine is an active agent in NSCLC. Single-agent gemcitabine has a progression-free survival (PFS) ranging between 2.5 and 4.25 months in advanced NSCLC, and the median survival is 4.4–7 months in the first-line setting for patients over the age of 70.11-13 Phase III trials of gemcitabine in the second-line setting for advanced NSCLC have not been performed, but in phase II studies, the median time to progression is 2.5 months, with a median overall survival of 9.5 months and an overall response rate is 18.5% . 14 Although gemcitabine historically has been considered to be purely immunosuppressive, preclinical studies have indicated that gemcitabine increases antigen cross-presentation, as well as increases the percentage of intratumor primed tumor-specific CD8 T cells without increasing functional tolerance. 15  \nCONTACT Rachel E. Sanborn, M.D.  [Rachel.sanborn@providence.org](Rachel.sanborn@providence.org); Bernard A. Fox, Ph.D.  Bernard.fox@providence.org  Robert W. Franz Cancer Center, Earle A. Chiles Research Institute, Provi","cbCaisJfmrOc3CO5","https://ap.wps.com/l/cbCaisJfmrOc3CO5","pdf",2760283,12,"English","# Abstract\n# Introduction\n## Checkpoint inhibitors and need for improved approaches\n## Rationale for gemcitabine in NSCLC\n# Materials and methods\n## Patients","[{\"question\":\"What does the study suggest about predicting response in advanced NSCLC?\",\"answer\":\"Cell-to-cell relationships in the tumor microenvironment provide significantly better predictive power than PD-L1 expression, TMB, or gene expression profiles.\"},{\"question\":\"What immune feature at baseline was associated with better treatment outcome?\",\"answer\":\"Higher frequencies of regulatory T cells near CD3 T cells at baseline correlated with improved outcome (p \\u003c 0.05).\"},{\"question\":\"How did the tumor inflammation score relate to disease response?\",\"answer\":\"Combining the Treg/T cell relationship metric with overall T-cell density produced a tumor inflammation score that correlated with disease response (p \\u003c 0.002).\"}]","Novel multiplex immunofluorescence-based tumor inflammation score provides apparent predictive biomarker in a phase I/II study of pembrolizumab with gemcitabine | PDF",1790095242,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4ea62f38ed2d276875850c57babc091d.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e837a96d0d181c327eea72b55a36ec20.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9e2970e694392c0cbdd629e84b490e8a.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/90e7efa628de4df92c21a21af9cd0c41.webp",980,1306]